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Negative symptoms and cognitive impairment associated with schizophrenia are strongly
associated with poor functional outcome and reduced quality of life and remain an unmet
clinical need. Cariprazine is a dopamine D3/D2 receptor partial agonist with preferential binding
to D3 receptors, recently approved by the FDA for the treatment of schizophrenia and manic or
mixed episodes associated with bipolar I disorder. The aim of this study is to evaluate effects of
cariprazine in an animal model of cognitive deﬁcit and negative symptoms of schizophrenia.
Following sub-chronic PCP administration (2 mg/kg, IP for 7 days followed by 7 days drug-free),
female Lister Hooded rats were administered cariprazine (0.05, 0.1, or 0.25 mg/kg, PO) or
risperidone (0.16 or 0.1 mg/kg, IP) before testing in novel object recognition (NOR), reversal
learning (RL), and social interaction (SI) paradigms. As we have consistently demonstrated, sub-
chronic PCP signiﬁcantly impaired behavior in these tests. Deﬁcits were signiﬁcantly improved
by cariprazine, in a dose dependent manner in the operant RL test with efﬁcacy at lower doses
in the NOR and SI tests. Locomotor activity was reduced at the highest doses of 0.1 mg/kg and
0.25 mg/kg in NOR and SI. Risperidone also reversed the PCP-induced deﬁcit in all tests. In
conclusion, cariprazine was effective to overcome PCP-induced deﬁcits in cognition and social
behavior in a thoroughly validated rat model in tests representing speciﬁc symptom domains ino.2015.11.016
CNP. All rights reserved.
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hester.ac.uk (J.C. Neill).
J.C. Neill et al.4schizophrenia patients. These ﬁndings support very recent results showing efﬁcacy of
cariprazine in the treatment of negative symptoms in schizophrenia patients.
& 2015 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Schizophrenia is thought to comprise 3 main symptom
clusters: positive symptoms (e.g., delusions, disorganized
speech, paranoia), negative symptoms (with expressive
deﬁcit and avolition domains, including blunted affect and
social withdrawal, respectively), and deﬁcits in cognition
(e.g., executive function, working memory, and attention)
(Kalkstein et al., 2010; Millan et al., 2014). While anti-
psychotics are generally effective in managing positive
symptoms, treatment of negative symptoms and cognitive
impairment remains a clinical challenge. Effective manage-
ment of neurocognitive deﬁcits and negative symptoms is a
critical component of successful schizophrenia treatment,
as these domains are strongly associated with poor quality
of life in schizophrenia patients (Savilla et al., 2008;
Tsapakis et al., 2015). Recent clinical trials have investi-
gated a number of adjunctive therapies for managing
cognitive and negative symptoms in patients with schizo-
phrenia. Unfortunately, these therapies have been largely
unsuccessful (Citrome, 2014), which underscores the impor-
tance of developing new antipsychotic treatments that can
effectively treat all 3 schizophrenia symptom domains.
Cariprazine is a potent dopamine D3 and D2 receptor
partial agonist with preferential binding to D3 receptors that
recently received approval by the FDA for the treatment of
schizophrenia and manic or mixed episodes associated with
bipolar I disorder. Cariprazine has been shown to be well
tolerated and effective in 3 recent Phase III trials in patients
with an acute exacerbation of schizophrenia (Durgam et al.,
2014, 2015; Kane et al., 2015) and demonstrated enhanced
efﬁcacy for negative symptoms, compared with other anti-
psychotics, in patients with high negative symptom scores
(Debelle et al., 2015). The D3 receptor is thought to play a
role in mood and cognition (Gross and Drescher, 2012) and
cariprazine was developed based on the hypothesis that
high afﬁnity at D3 and D2 receptors may provide beneﬁts in
the treatment of affective and cognitive deﬁcits associated
with schizophrenia and bipolar disorder (Gyertyán et al.,
2008; Kiss et al., 2008). In vitro studies have demonstrated
that the afﬁnity of cariprazine for the D3 receptor is almost
an order of magnitude greater than for the D2 receptor (Kiss
et al., 2010). In vivo, cariprazine demonstrates high occu-
pancy of both D3 and D2 receptors at antipsychotic effective
doses in rats (Gyertyán et al., 2011) and clinically active
dose ranges in patients with schizophrenia (Slifstein et al.,
2013). This pharmacological proﬁle differs from other
atypical antipsychotics such as aripiprazole, clozapine,
olanzapine, and risperidone, which have varying levels of
in vitro afﬁnity for D3 receptors, but failed to show D3
receptor occupancy at clinically relevant doses (Caravaggio
et al., 2014; Graff-Guerrero et al., 2009; Mizrahi et al.,
2011).In animal studies, cariprazine shows potent antipsychotic-like
activity in amphetamine-induced hyperactivity, apomorphine-
induced climbing, and in conditioned avoidance models
(Gyertyán et al., 2011), demonstrating putative efﬁcacy against
positive symptoms of schizophrenia. Cariprazine also shows
antidepressant-like activity in chronic stress-induced models of
anhedonia (Duman et al., 2012; Papp et al., 2014); this anti-
anhedonic activity was at least partially mediated by the D3
receptor (Duman et al., 2012). These data suggest a role for the
D3 receptor in reward processing, which is thought to be
disrupted in schizophrenia and is part of the negative symptom
domains.
The disruption of glutamatergic function has been
hypothesized to play a major role in the pathophysiology
of schizophrenia (Olney et al., 1999). Consistent with this
theory, NMDA receptor antagonists such as phencyclidine
(PCP) have demonstrated the ability to induce psycho-
pathology similar to the symptoms of schizophrenia in
healthy individuals (Luby et al., 1959) and to exacerbate
the symptoms in patients with schizophrenia (Malhotra
et al., 1997). As a result, PCP-based models have been
increasingly used as a method of modeling schizophrenia
symptoms in animals. Unlike many other schizophrenia
models, PCP-based models are capable of inducing cognitive
impairment and deﬁcits in social interaction in addition to
aspects of positive symptoms (Meltzer et al., 2013; Neill
et al., 2010, 2014; Sams-Dodd, 1996). These features
provide a particularly relevant model of schizophrenia that
can be used to test the efﬁcacy of new antipsychotic
compounds across multiple schizophrenia symptom
domains.
Both acute and sub-chronic PCP administration can effec-
tively produce deﬁcits across all 3 major symptom clusters of
schizophrenia in rodent models. Indeed, results from the
acute model provide a clear indication of procognitive
effects of cariprazine and importantly showed a D3 receptor
mechanism. Cariprazine demonstrated antipsychotic-like
activity in hypermotility tests (Gyertyán et al., 2011) and
D3-dependent reversal of acute PCP-induced deﬁcits in social
recognition memory, spatial working memory, and atten-
tional set shifting (Zimnisky et al., 2013).
Repeated PCP administration may provide a more endur-
ing model of the symptoms of schizophrenia and represent
the chronic condition (Jentsch and Roth, 1999; Morris et al.,
2005; Neill et al., 2010). Previous work in our laboratory and
elsewhere has consistently demonstrated that a sub-chronic
PCP treatment regimen (2 mg/kg; twice daily for 7 days)
produces robust and persistent deﬁcits in behaviors in
female rats that correspond with the various domains of
cognition affected in the illness (attention, executive func-
tion, recognition memory) and reduced social behavior, an
aspect of negative symptoms (Neill et al., 2010, 2014).
These deﬁcits are robust, enduring, and reliably attenuated
by several atypical antipsychotic agents, but not by ﬁrst
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as anxiety (Grayson et al., 2007; Rajagopal et al., 2014).
However, in clinical practice, any beneﬁts of antipsychotics
on these domains are too small to translate into improved
outcome and quality of life in patients with schizophrenia
(Bobes et al., 2007; Keefe et al., 2007; Tsapakis et al.,
2015). Improved treatments are therefore urgently required
along with more thorough preclinical testing in a range of
animal models in tests of the different symptom domains.
Our overall aim in this study was to further investigate
the previously observed procognitive effects of cariprazine
and to study in some detail the efﬁcacy of acute doses of
cariprazine to reverse cognitive and social behavior deﬁcits
in a more clinically relevant, and well-validated model that
utilizes sub-chronic PCP administration to mimic the chronic
cognitive impairment and negative symptoms of schizophre-
nia. The effects of cariprazine on visual recognition mem-
ory, and problem solving and reasoning, 2 different domains
of cognitive impairment known to be affected in patients
with schizophrenia, were assessed by the novel object
recognition (NOR) paradigm and operant reversal learning
test. The ability of cariprazine to restore normal social
function, an aspect of negative symptoms, in sub-chronic
PCP-treated rats was assessed to explore its potential to
improve social dysfunction in patients.
2. Experimental procedures
2.1. Animals
A total of 240 female Lister Hooded rats (Harlan, UK) weighing 225–
300 g and housed in groups of 5 under standard laboratory condi-
tions with a 12-h light/dark cycle (lights on at 7:00 AM) were used;
all testing was carried out in the light phase. All experiments were
carried out in accordance with the Animals Scientiﬁc Procedures Act
1986 and were approved by the University of Bradford ethical
review panel.
2.2. Drugs
Rats were pretreated with either 2.0 mg/kg PCP (Sigma, UK)
dissolved in 0.9% saline or vehicle (0.9% saline). PCP was adminis-
tered by intraperitoneal (IP) injection twice daily for 7 days followed
by a 7-day drug washout period (Figure 1). Cariprazine (Forest
Laboratories, Inc., New York, NY, USA) was prepared in a dose
volume of 1 mL/kg and suspended in 1% Tween-80. The drug was
administered orally (PO) 60 min prior to testing. Risperidone (Sigma,
UK), the positive control in these experiments, was prepared in aFigure 1 Study design and treatment groups. *Risperidone dose
0.1 mg/kg in reversal learning and social interaction experiments.minimum volume of acetic acid, made up to volume with distilled
water, and pH was adjusted to 6 with 0.1 M NaOH. Risperidone was
administered via the IP route 60 min prior to testing. For the NOR
study, risperidone was used at a dose of 0.16 mg/kg. The dose of
risperidone was reduced slightly to 0.1 mg/kg for other experiments
because we observed a reduction in behavioral activity at the
0.16 mg/kg dose in some animals (i.e., reduced exploration of
objects in the acquisition phase; Figure 2A, Table 1). A dose of
0.1 mg/kg of risperidone has been used in all of our subsequent
studies and has shown good efﬁcacy for reversal of PCP-induced
deﬁcits. In all experiments, the appropriate vehicle treatment was
used. All drug doses were calculated as base equivalent weight.2.3. Behavioral tests
2.3.1. Novel object recognition paradigm
The NOR test was performed as previously described in detail
(Grayson et al., 2007; Snigdha et al., 2010). Brieﬂy, rats (N=60; 50
PCP- and 10 vehicle-treated) were habituated in groups to an empty
test box for 1 h on day 1. Following an additional 3-min habituation
period on day 2, rats were given two 3-min trials separated by a
1-min interval in the home cage. In the ﬁrst (acquisition) trial,
animals were placed in the test box and allowed to explore
2 identical objects (A1 and A2). In the second (retention) trial,
animals were placed in the test box with 1 duplicate familiar object
from the acquisition phase (to avoid olfactory trails) and 1 novel
object. Cariprazine 0.05, 0.1, or 0.25 mg/kg (PO), risperidone
0.16 mg/kg (IP), or vehicle was administered 60 min prior to
testing. Behavior was ﬁlmed and scored by a trained experimenter
who was blinded to the treatment groups. Total object exploration
time (deﬁned as the duration of time animals spent licking, snifﬁng,
or touching the object but not including time spent standing or
sitting on or leaning against the object) was recorded for each of
the familiar and novel objects in the acquisition and retention
trials; locomotor activity (deﬁned as movement, measured by the
number of lines crossed in both trials) and discrimination index
(deﬁned as the difference in time spent exploring the novel and the
familiar objects divided by total time spent exploring both objects)
were also calculated. Any animal that failed to explore one or both
of the objects in the acquisition trial was excluded from the ﬁnal
analysis.2.3.2. Reversal learning task paradigm
Rats (N=60) maintained at 90% free-feeding weight were trained to
perform an operant reversal learning task by a method previously
described in detail (Abdul-Monim et al., 2003). Brieﬂy, following
habituation of the animals to test chambers, rats were trained to
respond for a food reward (45 mg Noyes pellets, PJ Noyes Company
Inc., Sandown Chemical Ltd., Kingston upon Thames, UK) on a ﬁxed
ratio 1 (FR1) schedule of reinforcement so that pressing either of
2 active levers delivers a food pellet. Once rats had acquired a leverwas 0.16 mg/kg in novel object recognition experiments and
IP, intraperitoneal, PCP, phencyclidine, PO, per os.
Figure 2 Mean exploration time7standard error of the mean (SEM) for (A) 2 identical objects in the acquisition phase and (B) 1
familiar and 1 unfamiliar object in the retention phase of the novel recognition test following acute treatment with vehicle (VEH),
cariprazine (CAR), or risperidone (RIS) in sub-chronic phencyclidine (PCP)-treated rats (n=6 animals in the cariprazine 0.25 mg/kg
group and n=8–10 in all other treatment groups; rats not exploring objects were excluded from ﬁnal analysis). (C) Mean
discrimination index7SEM and (D) mean number of line crossings7SEM in the acquisition and retention phases are also shown. For
(A) and (B), data were analyzed by post-hoc Student t test; *Po0.05; **Po0.01; ***Po0.001 for time spent exploring familiar vs
novel object. For (C) and (D), data were analyzed by analysis of variance and post-hoc least signiﬁcant difference t test; *Po0.05;
**Po0.01; ***Po0.001 for reduction in (C) discrimination index or (D) number of line crossings vs VEH; #Po0.05 for increase in
discrimination index and line crossings vs PCP+VEH.
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lever (only one was active) for food delivery. The active lever varied
from day to day using a pseudorandom Gellerman schedule; this
phase of training lasted approximately 2 weeks. Next, rats were
trained to press either the left or right lever for food delivery
according to the presence or absence of a visual cue (stimulus LED
light above lever). Sessions were terminated after 128 total
responses (approximately 30 min). Rats were trained once daily,
5 days per week, until they reached Z90% correct responding, with
each lever being active on Z3 consecutive days (generally
achieved within 2 weeks) after which rats were trained similarly
on the opposite reward contingency (i.e., the presence or absence
of visual cue). Before each reversal task session, a full 30-min
operant training session was conducted as described above to
ensure stable responding. For reversal task sessions, rats were ﬁrst
pretreated with twice-daily PCP (n=50) or vehicle (n=10) as
described above and then treated acutely with vehicle or test
compound (cariprazine 0.5, 0.1, or 0.25 mg/kg PO or risperidone
0.1 mg/kg IP) before being tested in the 2 reversal learning task
phases. The percentage of correct responses was calculated in each
phase. In the initial phase of the reversal task session, the reward
contingency was the same as the previous day and the test was
terminated at 5 min or when the animal had earned 20 pellets of
food. Following the initial phase, the rat remained in the test
chamber for a 2-min time-out period in which the house light was
extinguished to serve as a cue that the rule was about to change. In
the reversal phase, the reward contingency was reversed and the
test repeated as described above. In general, animals underwent4–6 reversal task sessions prior to beginning the drug studies to
ensure a stable level of performance in both phases of the task.
Cariprazine and risperidone were tested approximately 4 weeks
after sub-chronic PCP treatment.2.3.3. Social interaction paradigm
The social interaction test was performed in a square Plexiglas
open-ﬁeld box (52 52 31 cm) with black walls and a white ﬂoor
with black gridlines forming 9 identical squares. Rats (test animals,
n=60; conspeciﬁcs, n=60) were habituated to the test environ-
ment for 20 min per day for 3 days prior to testing. The ﬁrst social
interaction experiment occurred approximately 1 week after sub-
chronic PCP treatment. On the test day, sub-chronic vehicle-
treated rats (n=10) received an acute dose of vehicle while PCP-
treated rats (n=50) received acute doses of vehicle, cariprazine
0.05, 0.1, or 0.25 mg/kg PO, or risperidone 0.1 mg/kg IP 60 min
prior to testing. Two weight-matched rats (one treated test rat and
one conspeciﬁc), unfamiliar with each other, were placed in the
test arena together with an unfamiliar object (e.g., an unopened
drink can) for a 10-min period, and the duration of various
behaviors in the drug-treated rat were recorded and scored using
behavioral scoring software (Hindsight, Scientiﬁc Programming
Services, Wokingham, UK). Behavior was ﬁlmed and scored by a
trained experimenter who was blinded to the treatment groups.
Recorded behaviors included following (moving after the conspe-
ciﬁc in the arena), investigative snifﬁng behavior (snifﬁng any part
of the conspeciﬁc's body), avoidance (actively turning away when
Table 1 Total exploration time in the acquisition and
retention trials in the novel object recognition test
following acute treatment with vehicle or cariprazine in
sub-chronic PCP-treated rats (n=6 animals in the car-
iprazine 0.25 mg/kg group and n=8–10 in all other
treatment groups).
Treatment Total exploration time (s),
mean7SEM
Acquisition trial Retention trial
Vehicle+vehicle 33.173.8 26.974.1
PCP+vehicle 35.873.7 29.775.8
PCP+cariprazine
0.05 mg/kg
32.473.5 32.373.7
PCP+cariprazine
0.1 mg/kg
31.474.7 25.173.1
PCP+cariprazine
0.25 mg/kg
18.271.8 10.272.8#
PCP+risperidone
0.16 mg/kg
22.875.3 35.176.5
Data were analyzed by ANOVA and post-hoc least signiﬁcant
difference t test. PCP, phencyclidine; SEM, standard error of
the mean.
Po0.05 vs vehicle.
#P=0.09 vs vehicle.
7Effects of cariprazine, a novel antipsychoticthe conspeciﬁc approached), object exploration (investigation of
the unfamiliar object placed in the center of the arena), and line
crossings (number of lines crossed by the rat).
2.4. Statistical analysis
All data are expressed as mean7SEM. NOR data were analyzed via
2-way analysis of variance (ANOVA) with factors of drug and
exploration time of the 2 objects (2 identical objects in the
acquisition phase and novel and familiar objects in the retention
phase) and via 1-way ANOVA (for locomotor activity and discrimina-
tion index). Time spent exploring the objects was analyzed by a
paired Student t-test and post-hoc analysis was conducted following
a signiﬁcant 1-way ANOVA by least signiﬁcant difference t test (for
locomotor activity and discrimination index). Reversal learning data
were arcsine transformed then analyzed via 1-way ANOVA to detect
main effect of drug treatment in the initial and reversal phases of
the task. When a signiﬁcant effect (Po0.05) was detected, a post-
hoc least signiﬁcant difference t test was performed to compare
treatment groups with the appropriate control group. Social inter-
action data were analyzed via 1-way ANOVA followed by Dunnett's t
test to detect the effect of drug treatment (dependent variable) on
various behaviors (ﬁxed factor) observed during the test. Statistical
comparisons deﬁned statistical signiﬁcance as Po0.05.
3. Results
3.1. Effect of cariprazine on novel object
recognition
An overall 2-way ANOVA did not reveal a signiﬁcant inter-
action between treatment and object exploration during
the acquisition phase. In addition, there were no signiﬁcant
differences in the exploration time of 2 identical objects forany group (Figure 2A). In the retention phase, the 2-way
ANOVA showed a signiﬁcant interaction between treatment
and object exploration (F(5,45)=4.1; Po0.01). Vehicle-
treated rats spent signiﬁcantly more time exploring the
novel object compared with the familiar object (Po0.001),
whereas rats treated with sub-chronic PCP showed deﬁcits
in the ability to discriminate between novel and familiar
objects (Figure 2B). The sub-chronic PCP-induced impair-
ment in NOR was reversed by cariprazine 0.05 mg/kg
(Po0.01), cariprazine 0.1 mg/kg (Po0.05), and risperidone
0.16 mg/kg (Po0.05). The highest dose of cariprazine
(0.25 mg/kg) did not signiﬁcantly attenuate the PCP-
induced impairments in NOR (Figure 2B). A 1-way ANOVA
found a signiﬁcant effect of drug treatment on the dis-
crimination index (F(5,50)=2.4; Po0.05). There was a sig-
niﬁcant reduction in the discrimination index in the sub-
chronic PCP-treated rats compared with controls (Po0.05)
that was signiﬁcantly attenuated by administration of
cariprazine at the low and middle doses (0.05 and 0.1 mg/
kg, Po0.05). (Figure 2C).
Locomotor activity, as assessed by the total number of line
crossings in both trials, was signiﬁcantly reduced in rats
treated with sub-chronic PCP and vehicle (Po0.05) and the
higher doses of cariprazine (0.1 mg/kg, Po0.01; 0.25 mg/kg,
Po0.001; Figure 2D) compared with vehicle. The lowest dose
of cariprazine (0.05 mg/kg) signiﬁcantly reversed PCP-
induced deﬁcits in NOR without any signiﬁcant effect on
locomotor activity (overall 1-way ANOVA: F(5,50)=6.8;
Po0.001). Treatment with risperidone (0.16 mg/kg) signiﬁ-
cantly restored the total number of line crossings to control
levels when compared with the PCP control group (Po0.05)
(Figure 1D). There was a signiﬁcant effect of drug treatment
on total exploration time in both the acquisition
(F(5,50)=2.4; P=0.05) and retention (F(5,50)=2.6; Po0.05)
trials. Post-hoc analysis revealed a signiﬁcant reduction in
total exploration time in the acquisition and retention trials
following treatment with the highest dose of cariprazine
(0.25 mg/kg) compared with the vehicle control (Po0.05).
Only 6/10 rats were included in the ﬁnal analysis at this dose
due to lack of object exploration in the acquisition trial
(Table 1).3.2. Effect of cariprazine on reversal learning
In the initial phase of the reversal learning task, there was
no effect of drug treatment on the percentage of correct
responses (Figure 3A). In the reversal phase of the task,
1-way ANOVA revealed a signiﬁcant effect of drug treatment
on correct responses (F(5, 49)=5.4; Po0.01). PCP treatment
resulted in signiﬁcantly impaired performance compared
with vehicle (Po0.01) (Figure 3A). The 2 higher doses of
cariprazine (0.1 mg/kg, Po0.05; 0.25 mg/kg, Po0.01) sig-
niﬁcantly attenuated this impairment, such that animals
were performing at control levels (Figure 3A); treatment
with risperidone 0.1 mg/kg also signiﬁcantly reversed PCP-
induced impairments in this task (Po0.01). No treatment
effects were observed with the lowest dose of cariprazine
(0.05 mg/kg) and these animals were still signiﬁcantly
impaired compared with vehicle (Po0.01). There were no
signiﬁcant effects of any drug treatment on the total
number of lever presses in this experiment (Figure 3B).
Figure 3 (A) Percentage of correct responses7standard error of the mean (SEM) in the reversal learning test following treatment
with vehicle (VEH), cariprazine (CAR), or risperidone (RIS) in sub-chronic phencyclidine (PCP)-treated rats (n=8–10 animals per
group). (B) Mean total lever presses7SEM from the same experiment. For (A), data were analyzed by analysis of variance followed
by least signiﬁcant difference t test; **Po0.01 for reduction in performance in the reversal phase vs VEH; #Po0.05; ##Po0.01 for
treatment vs PCP alone in the reversal phase.
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In this set of experiments, sub-chronic PCP treatment led to
disrupted social behaviors in female rats; 1-way ANOVA
revealed a signiﬁcant effect of drug treatment on avoiding
behavior (F(5,57)=3.6; Po0.01), following behavior
(F(5,57)=2.5; Po0.05), snifﬁng behavior (F(5,57)=2.8;
Po0.05), and object exploration time (F(5,57)=8.4;
Po0.001). Post-hoc analysis demonstrated that sub-
chronic PCP treatment resulted in a signiﬁcant increase in
avoiding behavior (Po0.01; Figure 4A), a signiﬁcant reduc-
tion in following behavior (Po0.05; Figure 4B) and object
exploration (Po0.05; Figure 4D) compared with vehicle;
sub-chronic PCP treatment also reduced snifﬁng behavior
(Figure 4C), but this effect did not achieve statistical
signiﬁcance (P=0.09).
At all doses tested, cariprazine (0.05 mg/kg, 0.1 mg/kg,
and 0.25 mg/kg) reversed PCP-induced alterations in avoid-
ing behavior (Po0.05 for each; Figure 4A) and object
exploration (Po0.001 for 0.05 and 0.1 mg/kg and Po0.05
for 0.25 mg/kg; Figure 4D). Cariprazine at 0.05 mg/kg
signiﬁcantly reversed PCP-induced deﬁcits in following
behavior compared with vehicle (Po0.05; Figure 4B).
Higher doses of cariprazine also attenuated deﬁcits infollowing behavior, but these treatment effects did not
reach statistical signiﬁcance. A trend towards reduced
duration of snifﬁng behavior was observed in PCP-treated
rats compared with vehicle (Figure 4C, P=0.09); this
snifﬁng deﬁcit was restored to vehicle control levels with
cariprazine, however, no signiﬁcant treatment effects were
observed. Risperidone at 0.1 mg/kg also signiﬁcantly atte-
nuated PCP-induced reductions in avoiding behavior
(Po0.05) and object exploration (Po0.001) but did not
show signiﬁcant effects on following or snifﬁng behavior.
There was a signiﬁcant effect of drug treatment on
locomotor activity as measured by the number of line
crossings (1-way ANOVA: F(5,57)=9.9; Po0.001). Rats trea-
ted with sub-chronic PCP, cariprazine 0.05 mg/kg, or risper-
idone 0.1 mg/kg did not show signiﬁcant effects compared
with vehicle. However, cariprazine 0.1 (Po0.01) and
0.25 mg/kg (Po0.001) signiﬁcantly reduced the number of
line crossings compared with vehicle (Figure 4E).4. Discussion
This study assessed the ability of cariprazine to reverse
deﬁcits induced by sub-chronic PCP in cognitive function
Figure 4 Mean duration7standard error of the mean (SEM) of (A) avoiding, (B) following, (C) snifﬁng, (D) object exploration, and
(E) mean number7SEM of line crossings in the social interaction test following treatment with vehicle (VEH) or cariprazine (CAR) in
sub-chronic phencyclidine (PCP)-treated rats (n=8–10 animals per group). Data were analyzed by analysis of variance followed by
Dunnett's t test. *Po0.05; **Po0.01; ***Po0.001 for difference vs VEH; #Po0.05; ###Po0.001 for difference vs PCP alone.
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treatment regimen has been thoroughly validated in our
laboratory and elsewhere (see below) and offers certain
advantages over acute PCP exposure for modeling the
cognitive and negative symptoms of schizophrenia.
While both acute and chronic PCP exposure are known to
disrupt cognition and social behavior, chronic exposure
appears to produce robust and enduring effects that are
more consistent with the chronic symptoms observed in
patients with schizophrenia (Jentsch and Roth, 1999; Neill
et al., 2010). Unlike acute administration, repeated PCP
exposure has been associated with lasting neurochemical
changes in the prefrontal cortex, including reduced cerebral
blood ﬂow and glucose utilization (Hertzmann et al., 1990;
Wu et al., 1991), and decreased dopamine neurotransmis-
sion (Jentsch and Roth, 1999; Jentsch et al., 1997). In
addition, the sub-chronic PCP dosing regimen used here
produces pathophysiological deﬁcits in parvalbumin-
immunoreactivity (PV) in the hippocampus and prefrontalcortex in adult rats that co-occur with cognitive and social
behavioral changes (Abdul-Monim et al., 2007; Jenkins
et al., 2008). These PV deﬁcits are restored by sub-
chronic treatment with a novel KV3.1 channel modulator
and return to reduced levels on cessation of this drug
treatment, demonstrating a previously unconﬁrmed plasti-
city of PV in this model (Leger et al., 2015). Proton
magnetic resonance spectroscopy and ex vivo HPLC studies
have demonstrated reduced N-acetylaspartate (NAA) in sub-
chronic PCP-treated rats providing further validation of the
NMDA receptor antagonist model of relevance to schizo-
phrenia pathophysiology (Bustillo et al., 2012; Reynolds
et al., 2005). More recently, magnetic resonance imaging
results in rats found that sub-chronic PCP exposure was
linked to highly localized morphological abnormalities in
areas of the brain associated with the pathogenesis of
schizophrenia; these effects were accompanied by atten-
tional impairments (Barnes et al., 2014). Considering that
the cognitive dysfunction associated with schizophrenia has
J.C. Neill et al.10been associated with “hypofrontality” and reduced dopa-
mine transmission in the prefrontal cortex (Jentsch and
Roth, 1999), deﬁcits caused by sub-chronic PCP exposure
appear to be highly relevant to the chronic disease state
associated with schizophrenia.
Another advantage of sub-chronic vs acute PCP adminis-
tration is the ability to evaluate behavioral deﬁcits in a
drug-free state. The deﬁcits produced by this sub-chronic
PCP regimen have been found to persist for at least 6 months
(Grayson personal communication); as such, a 1-week PCP
washout period was included before behavioral testing in
this study to eliminate any potentially confounding effects
on behavior as a result of the presence of PCP. All these
factors suggest that sub-chronic PCP administration relative
to acute treatment results in robust, enduring deﬁcits, and
provides a useful model that better mimics the true chronic
nature of schizophrenia symptomatology, particularly
regarding its ability to model negative symptoms and
cognitive dysfunction.
The NOR task, a measure of visual recognition memory, is
sensitive to disruption by NMDA receptor antagonists and
shows good predictive ability for new antipsychotic agents
(Grayson et al., 2015). Results from in vivo microdialysis
experiments have suggested that PCP-induced deﬁcits in NOR
are associated with hypodopaminergic dysfunction in the
prefrontal cortex (Snigdha et al., unpublished ﬁndings) (Neill
et al., 2010), consistent with observations in schizophrenia
patients (Jentsch and Roth 1999). Effects of sub-chronic PCP
treatment (2 mg/kg of PCP administered twice daily for
7 days) in the current study were consistent with previous
ﬁndings showing that PCP produced signiﬁcant deﬁcits in the
NOR paradigm. This impairment was reversed by administra-
tion of cariprazine 0.05 and 0.1 mg/kg; there were no effects
on line crossings in the cariprazine 0.05 mg/kg group,
conﬁrming that effects in this dose group were not con-
founded by changes in locomotor activity. The dose of
0.1 mg/kg signiﬁcantly reversed PCP-induced NOR deﬁcits
in spite of signiﬁcantly reducing line crossings, with no
reduction in total object exploration. In contrast, the highest
dose of cariprazine tested (0.25 mg/kg) signiﬁcantly reduced
line crossings and markedly attenuated object exploration,
indicative of mild sedative effects in this paradigm at this
dose. A comparable reduction in locomotor activity was also
observed in the social interaction study. At the highest dose,
cariprazine 0.25 mg/kg impaired performance in the NOR
test such that only 6/10 rats were included in the ﬁnal
analysis, further conﬁrming behavioral impairment at this
dose. Risperidone at 0.16 mg/kg also improved PCP-induced
deﬁcits in the NOR paradigm.
In the reversal learning paradigm, rats are tested for
their ability to abandon a previously learned reward con-
tingency and acquire a new strategy for obtaining the
reward; this behavioral task requires animals to show
cognitive ﬂexibility, attention, and motivation (Neill
et al., 2010). Deﬁcits in this ability are linked to dysfunction
in the prefrontal cortex (Boulougouris et al., 2007), and
resemble impairments observed in schizophrenia patients
on the Wisconsin Card Sorting test (Pantelis et al., 1999).
This model also shows predictive ability of clinical efﬁcacy
as sub-chronic PCP-induced deﬁcits are attenuated by
certain new agents (but not ﬁrst generation antipsychotic
agents like haloperidol and chlorpromazine) (Neill et al.,2010). Consistent with all our previous studies, sub-chronic
PCP did not affect performance in the initial phase, but it
signiﬁcantly impaired the ability of rats to switch learning
strategies in the reversal phase. Cariprazine at doses of
0.1 and 0.25 mg/kg, but not 0.05 mg/kg, signiﬁcantly
attenuated the PCP-induced impairments in reversal
learning.
Interestingly, even the highest dose of cariprazine
(0.25 mg/kg) did not appear to have any effect to impair
this behavior, as there was no reduction of lever presses in
any group and performance was restored to baseline levels,
in contrast to its effects in NOR. We have observed this
phenomenon previously with the antipsychotic asenapine
(McLean et al., 2010; Snigdha et al., 2011). Rats in the
reversal learning task are food deprived and highly moti-
vated by the nature of the task, and we routinely observe
improvement of PCP-induced deﬁcits at higher doses than in
NOR, indeed even at doses that markedly reduce object
exploration, as observed here. Risperidone at 0.1 mg/kg
also demonstrated signiﬁcant attenuation of PCP-induced
deﬁcits in reversal learning. These results show that car-
iprazine has efﬁcacy to improve PCP-induced deﬁcits in
executive function in a manner similar to the positive
control, risperidone, in a model of relevance to schizophre-
nia. It is important to note that this dose of risperidone is
not sufﬁcient to occupy dopamine D2 receptors at a
clinically meaningful level, but rather its efﬁcacy in these
tests is more likely due to serotonergic mechanisms, with
5-HT2A receptor blockade playing a more prominent role
(see Neill et al. (2014) for a full discussion of this issue).
Patients with schizophrenia suffer from a number of
negative symptoms, which include avolition, poverty of
speech, and social withdrawal. The precise neural mechan-
isms underlying negative symptoms in schizophrenia are not
entirely clear, although frontal lobe dysfunction is widely
suspected to play a role (Semkovska et al., 2001). The
modeling of many of the negative symptoms in animals has
presented a challenge, although PCP treatment has been
found to consistently induce social withdrawal in rodents
(Gururajan et al., 2010; Neill et al., 2010, 2014). Sub-
chronic PCP treatment regimens have previously been
shown to impair social behavior, an effect rescued by
antipsychotics (Sams-Dodd, 1996; Snigdha and Neill,
2008a, 2008b). We have demonstrated a role for 5-HT1A
receptor mechanisms in the restoration of PCP-induced
social behavior deﬁcits (Snigdha and Neill, 2008b) and the
current ﬁndings extend this to D3 receptors, although
further studies are required to verify this. Such work will
be important to identify novel targets that can improve
certain aspects of negative symptoms in patients.
In the present study, sub-chronic PCP treatment produced
signiﬁcant increases in avoiding behavior and reduced
following behavior, and a nonsigniﬁcant reduction in snifﬁng
behavior (P=0.09). Cariprazine reversed the PCP-induced
increase in avoiding behavior (all doses) and the reduction
in following behavior (0.05 mg/kg). Furthermore, enhanced
snifﬁng was observed at 0.05 mg/kg of cariprazine to a level
greater than in controls, although these effects did not
achieve statistical signiﬁcance.
Risperidone signiﬁcantly attenuated PCP-induced avoid-
ance, but failed to attenuate deﬁcits in following behavior.
These results suggest that cariprazine may have a speciﬁc
11Effects of cariprazine, a novel antipsychoticand selective effect to attenuate a range of social behavior
deﬁcits induced by sub-chronic PCP, with broader effects to
restore these deﬁcits than the atypical antipsychotic risper-
idone. In particular, cariprazine at 0.05 mg/kg reversed
PCP-induced social behavior deﬁcits in the absence of any
effect on line crossings. Enhanced efﬁcacy compared with
risperidone is in agreement with recent clinical trial data
showing increased efﬁcacy of cariprazine over risperidone in
patients with high negative symptom scores (Debelle et al.
2015). This concurrence with effects in patients strengthens
the translational value of our model (see Neill et al. (2010,
2014) for full reviews). Indeed efﬁcacy of risperidone in
our model is at low, non-clinically relevant, doses as
explained above.
Further studies are needed to deﬁne the pharmacological
mechanisms responsible for the effects of cariprazine on
PCP-induced deﬁcits in cognition and social behavior,
although it seems likely that dopamine D3 receptors play a
role. Based on their preferential expression in areas of the
brain thought to be responsible for modulation of mood and
cognition, it has been hypothesized that D3 receptor
antagonists may be effective in treating the cognitive and
negative symptoms of schizophrenia (Gross and Drescher,
2012; Gyertyán et al., 2008; Joyce and Millan, 2005;
Sokoloff et al., 2006). In further support of this hypothesis,
D3 receptor agonists have been shown to impair cognition
(Gross et al., 2013; Nakajima et al., 2013) and D3 receptor
agonists has been linked to decreased regional cerebral
blood ﬂow in the prefrontal cortex (Black et al., 2002) and
inhibition of dopamine release and synthesis in the frontal
cortex (Gobert et al., 1995; Millan et al., 2008), effects
which bear similarity to the neurochemical changes
observed following chronic PCP treatment (Jentsch and
Roth, 1999). Since deﬁcits in cognitive behavior following
sub-chronic PCP treatment are known to be accompanied by
reductions in dopamine neurotransmission in the prefrontal
cortex (Snigdha et al., unpublished results), the procogni-
tive effects of cariprazine may be related to regulation of
dopamine neurotransmission through D3 receptor antagon-
ism. Interestingly, cariprazine has also shown the ability to
reverse the effects of acute PCP exposure, which were
associated with increased dopamine release in prefrontal
cortex in rats (Adham et al., 2012). Taken together, these
ﬁndings suggest that cariprazine may normalize both
increases and decreases in dopamine neurotransmission,
possibly due to the potent partial agonist properties at
dopamine D2 and D3 receptors. Potential involvement of D3
receptors in cariprazine-mediated improvement in cognitive
and negative symptom-like behavior are further supported
by experiments in D3 receptor knockout mice, in which
cariprazine demonstrated D3 receptor-mediated reversal of
PCP-induced deﬁcits in social recognition, working memory,
and executive functioning (Zimnisky et al., 2013), and in
studies of stress-induced anhedonia (Duman et al., 2012).
In addition to activity at dopamine D2 and D3 receptors,
cariprazine also exhibits partial agonist activity at the
serotonin 5-HT1A receptor. Previous experiments have impli-
cated the 5-HT1A receptor in restoration of sub-chronic PCP-
induced deﬁcits in reversal learning and social interaction
(McLean et al., 2009; Snigdha and Neill, 2008a, b). There-
fore, it is possible that afﬁnity for 5-HT1A receptors may also
play a role in the observed effects of cariprazine oncognitive dysfunction and negative symptom-like behavior
in rats. The combination of potent afﬁnity and partial
agonism at dopamine D3 and D2 receptors, as well as partial
agonist activity at 5-HT1A receptors, for cariprazine suggests
a promising pharmacological proﬁle for treating the cogni-
tive and negative symptoms associated with schizophrenia.
This study has several potential limitations. The animals
used were exclusively female, due in part to increased
sensitivity of female rats compared with male rats to the
behavioral effects of PCP, and enhanced performance of
female rats in cognitive tasks and social behavior testing
(Grayson et al., 2007; Sutcliffe et al., 2007; Wessinger,
1995). Clear sex differences in brain, behavior, and phar-
macokinetics exist in both rats and humans; it is possible
that different outcomes would be seen in male rats (Cahill,
2006). It is also important to point out the difﬁculty of using
laboratory animals housed in optimal conditions to fully
mimic a complex disease that may include genetic/neuro-
developmental predisposition, comorbid drug abuse, and/or
polypharmacy (Neill et al., 2010). Indeed, the sub-chronic
PCP model is limited by the lack of genetic or neurodeve-
lopmental components. Therefore, further testing in more
comprehensive schizophrenia models is warranted. Models
incorporating developmental disruption, such as maternal
immune activation, may be more accurate in simulating the
complex nature of schizophrenia and early through to
chronic stages of the illness (for recent review see Knuesel
et al. (2014)). In contrast to previous cariprazine/PCP
experiments, this study utilized sub-chronic administration
of PCP to better simulate the chronic symptoms of schizo-
phrenia; however, the test compounds (cariprazine and
risperidone) were administered as acute doses. Studies in
rats designed to explore the effects of chronic cariprazine
administration and its withdrawal will provide relevant
insights into the long-term efﬁcacy of this compound.
Furthermore, since patients in the clinical setting will have
had previous exposure to antipsychotics prior to cariprazine
treatment, animal studies should aim to incorporate this, as
this has an impact on brain and behavior. Indeed, a recent
study has shown that activated microglia, a marker of
neuroinﬂammation, are increased in brain regions of rats
chronically treated with clinically relevant doses of anti-
psychotics (Cotel et al., 2015).
In summary, cariprazine signiﬁcantly improved deﬁcits in
NOR, reversal learning, and social interaction induced by
sub-chronic PCP in female rats. These results suggest that,
in addition to its previously demonstrated antipsychotic
efﬁcacy in animal models (Gyertyán et al., 2011), caripra-
zine may be effective in treating negative symptoms and
several aspects of cognition associated with schizophrenia,
such as recognition memory and rule learning. The receptor
mechanisms by which these effects are mediated remain to
be identiﬁed, although the potent afﬁnity of cariprazine for
dopamine D3 receptors likely plays a role. The efﬁcacy of
cariprazine in adult patients with schizophrenia is supported
by randomized, controlled clinical trial results (Durgam
et al., 2014; Kane et al., 2015; Durgam et al., 2015). In
these studies, cariprazine demonstrated signiﬁcantly
greater improvement than placebo on positive, negative,
and cognitive symptom domains of the Positive and Negative
Syndrome Scale (PANSS) (Durgam et al., 2014; Kane et al.,
2015; Durgam et al., 2015). However, the effect of
J.C. Neill et al.12cariprazine on cognition and negative symptoms in patients
with schizophrenia needs further validation with analyses
speciﬁcally designed to assess these symptom domains.
Future animal studies exploring the efﬁcacy of cariprazine
across different domains of cognition and negative symp-
toms following acute and chronic dosing are warranted. In
addition, investigation in other animal models, particularly
incorporating a neurodevelopmental component, and in
animals previously exposed to antipsychotics, are likely to
enhance understanding of the long-term effects of caripra-
zine on these symptom domains.
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